iwNHL 2018 Session IV
Immunotherapy of Lymphoma
Session IV of iwNHL 2018 saw the discussion of improving immune responses and developing immunological agents against lymphomas from John Gribben, MD, DSc, FRCPath, Stephen Ansell, MD, PhD, and Robert Chen, MD.
Presentations
Targeting PD-1 in Immune Activated Situations
John Gribben
Barts Cancer Institute, London, UK
Barts Cancer Institute, London, UK
22 September, 2019
John Gribben, MD, DSc, FRCPath, from Barts Cancer Institute, London, UK, speaks on the strategies for improving anti-tumor immune responses against lymphoma.
New Immune Therapies for Lymphoma- (LAG-3/TIGIT/4-1BB/CD47/bi-specifics)
Stephen Ansell
Mayo Clinic, Rochester, MI
Mayo Clinic, Rochester, MI
22 September, 2018
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, updates us on novel, promising immunologic agents to target lymphoma.
Beyond PD-1 Blockade Alone - Combination Approaches
Robert Chen
City of Hope National Medical Center, Duarte, CA
City of Hope National Medical Center, Duarte, CA
22 September, 2018
Robert Chen, MD, from City of Hope National Medical Center, Duarte, CA, highlights some promising combination therapies for treating lymphoma.
